Indica
Backed by cutting edge technology, an uncompromising focus on ease-of-use and dedicated customer service, Indica Labs’ software and services are being used to make vital discoveries in pathology labs and research organizations around the world.

Tissue Microarray (TMA)

TMA (TISSUE MICROARRAY) ADD-ON

 

Product Overview

The TMA add-on provides a productivity-enhancing workflow for tissue microarray analysis by enabling automated, high-throughput, segmentation and batch analysis of whole slide TMA images.  The add-on can be used in conjunction with any of our cell-based analysis modules for brightfield or fluorescence, as well as our tissue classifier add-on for automated tumor detection.  In combination, these tools allow the user to automatically identify tumor, and quantify cell-based IHC, ISH, or Immunofluorescence assays within just the relevant tumor regions; eliminating the need for manual exclusion of non-tumor regions.

To learn more, watch this short demonstration video:

The TMA add-0n integrates seamlessly into the HALO® platform which is compatible with a number of  file formats.

Contact info@indicalab.com for product demonstration and pricing information or upload some images for a free trial.

TMA (TISSUE MICROARRAY) ADD-ON

The TMA add-on provides a productivity-enhancing workflow for tissue microarray analysis by enabling automated, high-throughput, segmentation and batch analysis of whole slide TMA images.  The add-on can be used in conjunction with any of our cell-based analysis modules for brightfield or fluorescence, as well as our tissue classifier add-on for automated tumor detection.  In combination, these tools allow the user to automatically identify tumor, and quantify cell-based IHC, ISH, or Immunofluorescence assays within just the relevant tumor regions; eliminating the need for manual exclusion of non-tumor regions.

To learn more, watch this short demonstration video:

Here are a few publications that cite the use of our TMA add-on. Your publication not on the list?  Drop us an email to let us know about it!

TitleAuthorsYearJournalApplicationHALO Modules
Prevalence of CD8+ cytotoxic lymphocytes in human neoplasmsBlessin NC, Spriestersbach P, Li W, Mandelkow T, Dum D, Simon R, Hube-Magg C, Lutz F, Viehweger F, Lennartz M, Fraune C, Nickelsen V, Fehrle W, Göbel C, Weidemann S, Clauditz T, Lebok P, Möller K, Steurer S, Izbicki JR, Sauter G, Minner S, Jacobsen F, Luebke AM, Büscheck F, Höflmayer D, Wilczak W, Burandt E, Hinsch A2020Cellular OncologyOncology, Immuno-oncologyMembrane, TMA
Linking epigenetic signature and metabolic phenotype in IDH mutant and IDH wildtype diffuse gliomaBuran Y, Filipski K, Bernatz S, Baumgarten P, Roller B, Zinke J, Zeiner PS, Ilina E, Senft C, Ronellenfitsch MW, Plate KH, Bähr O, Hattingen E, Steinbach JP, Mittelbron M, Harter PN2020Neuropathology and Applied NeurobiologyNeuroscienceMultiplex IHC, TMA
The prevalence and prognostic significance of estrogen receptor beta expression in non-small cell lung cancerEnwere EK, Dean ML, Li H, D'Silva A, Bebb DG2020Translational Lung Cancer ResearchOncologyCytonuclear, TMA
The role of WNT10B in normal prostate gland development and prostate cancerMadueke I, Hu W-Y, Hu D, Swanson SM, Griend DV, Abern M, Prins GS2019The ProstateOncologyMultiplex IHC, TMA
Mechanical regulation of glycolysis via cytoskeleton architecturePark JS, Burckhardt CJ, Lazcano R, Solis LM, Isogai T, Li L, Chen CS, Gao B, Minna JD, Bachoo R, DeBerardinis RJ, Danuser G2020NatureOncologyClassifier, Cytonuclear, TMA
Prognostic significance of mesothelin expression in colorectal cancer disclosed by area-specific four-point tissue microarraysShiraishi T, Shinto E, Nearchou IP, Tsuda H, Kajiwara Y, Einama T, Caie PD, Kishi Y, Ueno H2020Vichows ArchivOncologyCytonuclear, HALO AI, TMA
Kaiso (ZBTB33) subcellular partitioning functionally links LC3A/B, the tumor microenvironment, and breast cancer survivalSinghal SK, Byun JS, Park S, Yan T, Yancey R, Caban A, Hernandez SG, Hewitt SM, Boisvert H, Hennek S, Bobrow M, Ahmed SU, White J, Yates C, Aukerman A, Vanguri R, Bareja R, Lenci R, Farré PL, De Siervi A, Nápoles AM, Vohra N, Gardner K2021Communications BiologyOncologyCytonuclear, TMA
Prognostic and Predictive Value of Tumor-infiltrating Leukocytes and of Immune Checkpoint Molecules PD1 and PDL1 in Clear Cell Renal Cell CarcinomaStenzel PJ, Schindeldecker M, Teagscherer KE, Foersch S, Herpel E, Hohenfellner M, Hatiboglu G, Alt J, Thomas C, Haferkamp A, Roth W, Macher-Goeppinger S2020Translational OncologyOncology, Immuno-oncologyClassifier, Cytonuclear, TMA
Tumor cell PD-L1 expression is a strong predictor of unfavorable prognosis in immune checkpoint therapy-naive clear cell renal cell cancerMöller K, Fraune C, Blessin NC, Lennartz M, Kluth M, Hube-Magg C, Lindhorst L, Dahlem R, Fisch M, Eichenauer T, Riechardt S, Simon R, Sauter G, Büscheck F, Höppner W, Matthies C, Doh O, Krech T, Marx AH, Zecha H, Rink M, Steurer S, Clauditz TS2021International Urology and NephrologyImmuno-oncologyMultiplex IHC, TMA
Prognostic role of proliferating CD8+ cytotoxic Tcells in human cancersBlessin NC, Li W, Mandelkow T, Jansen HL, Yang C, Raedler JB, Simon R, Büscheck F, Dum D, Luebke AM, Hinsch A, Möller K, Menz A, Bernreuther C, Lebok P, Clauditz T, Sauter G, Marx A, Uhlig R, Wilczak W, Minner S, Krech T, Fraune C, Höflmayer D, Burandt E, Steurer S2021Cellular OncologyImmuno-oncologyHighplex FL, TMA
Epigenetic modifications precede molecular alterations and drive human hepatocarcinogenesisCzauderna C, Poplawski A, O'Roourke C, Castven D, Pérez-Aguilar B, Becker D, Heilmann-Heimbach S, Odenthal M, Amer W, Schmiel M, Drebber U, Binder H, Ridder D, Schindeldecker M, Straub B, Galle P, Andersen J, Thorgeirsson S, Park Y, Marquardt J2021JCI InsightOncologyCytonuclear, TMA
PLX3397 treatment inhibits constitutive CSF1R-induced oncogenic ERK signaling, reduces tumor growth, and metastatic burden in osteosarcomaSmeester BA, Slipek NJ, Pomeroy EJ, Laoharawee K, Osum SH, Larsson AT, Williams KB, Stratton N, Yamamoto K, Peterson JJ, Rathe SK, Mills LJ, Hudson WA, Crosby MR, Wang M, Rahramann EP, Moriarity SB, Largaespada DA2020BoneOncologyCytonuclear, TMA
Diagnostic and prognostic implications of a three-antibody molecular subtyping algorithm for non-muscle invasive bladder cancerJackson C, Chen L, Hardy C, Ren K, Visram K, Bratti V, Johnstone J, Sjödahl G, Siemens D, Gooding R, Berman D2021The Journal of Pathology: Clinical ResearchOncologyCytonuclear, TMA
Comprehensive clinicopathologic study of alpha fetoprotein-expression in a large cohort of patients with hepatocellular carcinomaRidder D, Weinmann A, Schindeldecker M, Urbansky L, Berndt K, Gerber T, Lang H, Lotz J, Lackner K, Roth W, Straub B2021International Journal of CancerOncologyCytonuclear, TMA
PIK3CA mutation and CNV status and post-chemoradiotherapy survival in patients with cervical cancerMartell K, McIntyre JB, Kornaga EN, Chan AMY, Phan T, Kobel M, Enwere EK, Dean ML, Ghatage P, Lees-Miller SP, Doll CM2020Gynecologic OncologyOncologyClassifier, Highplex FL, TMA
Tissue-resident FOLR2+ macrophages associate with tumor-infiltrating CD8+ T cells and with increased survival of breast cancer patientsRamos, R, Missolo-Koussou Y, Gerber-Ferder Y, Bromley C, Bugatti M, Nunez N, Tosello J, Richer W, Denizeau J, Sedlik C, Caudana P, Kotsias F, Niborski L, Viel S, Bohec M, Lameiras S, Baulande S, Lesage L, Nicolas A, Mesure D, Vincent-Salomon A, Reyal F, Dutertre C, Ginhoux F, Vimeux L, Donnadieu E, Buttard B, Galon J, Zelenay S, Vermi W, Guermonprez P, Piaggio E, Helft J2021bioRxivImmuno-oncologyCytonuclear, Highplex FL, TMA
T-regulatory cells predict clinical outcome in soft tissue sarcoma patients: a clinico-pathological studySmolle M, Herbsthofer L, Granegger B, Goda M, Brcic I, Bergovec M, Scheipl S, Prietl B, Pichler M, Gerger A, Rossmann C, Riedl J, Tomberger M, López-García P, El-Heliebi A, Leithner A, Liegl-Atzwanger B, Szkandera J2021British Journal of CancerOncologyHighplex FL, TMA
Tertiary lymphoid structures critical for prognosis in endometrial cancer patients - a TransPORTEC studyHoreweg N, Workel, H, Loiero D, Church D, Vermij L, Léon-Castillo A, Krog R, de Boer S, Nout R, Powel M, Mileshkin L, MacKay H, Leary A, Singh N, Jürgenliemk-Schulz I, Creutzberg C, Koelzer V, Nijman H, Bosse T, Bruyn M2021Research SquareMultiplex IHC, HALO AI, TMA
Genomic analysis of Vascular Invasion in Hepatocellular Carcinoma (HCC) Reveals Molecular Drivers and Predictive BiomarkersKrishnan MS, Rajan KD A, Park J, Arjunan V, Marques FJG, Bermudez A, Girvan OA, Hoang NS, Yin J, Nguyen MH, Kothary N, Pitteri S, Felsher DW, Dhanasekaran R2020HepatologyOncologyMultiplex IHC, TMA
B7-H3 immune checkpoint expression is a poor prognostic factor in colorectal carcinomaLu Z, Zhao Z-X, Cheng P, Huang F, Guan X, Zhang M-G, Chen H-P, Liu Z, Jiang Z, Zheng Z-X, Zou S-M, Wang X-S2020Modern PathologyImmuno-oncologyMultiplex-IHC, TMA

Click here to initiate your free proof-of-concept HALO® image analysis.